Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis evaluated onset of action and maintenance of respons...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2371045 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115056617914368 |
|---|---|
| author | Neil J. Korman Richard B. Warren Jerry Bagel April W. Armstrong Melinda Gooderham Bruce Strober Diamant Thaçi Akimichi Morita Shinichi Imafuku Peter Foley Howard Sofen Min Zheng Lauren Hippeli Renata M. Kisa Subhashis Banerjee Andrew Blauvelt |
| author_facet | Neil J. Korman Richard B. Warren Jerry Bagel April W. Armstrong Melinda Gooderham Bruce Strober Diamant Thaçi Akimichi Morita Shinichi Imafuku Peter Foley Howard Sofen Min Zheng Lauren Hippeli Renata M. Kisa Subhashis Banerjee Andrew Blauvelt |
| author_sort | Neil J. Korman |
| collection | DOAJ |
| description | Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis evaluated onset of action and maintenance of response in patients randomized to deucravacitinib and placebo only. Methods: Adults with moderate to severe plaque psoriasis at baseline were randomized 1:2:1 to oral placebo, deucravacitinib, or apremilast. Onset of action was determined through changes from baseline in mean PASI, BSA, BSA × sPGA, and DLQI. Maintenance of response was assessed using PASI 75, PASI 90, PASI 100, sPGA 0/1, and sPGA 0 response rates through Week 52 in patients who were treated continuously with deucravacitinib, crossed over from placebo to deucravacitinib at Week 16, or received deucravacitinib and achieved PASI 75 by Week 24. Results: Deucravacitinib showed significantly higher increases in mean percent change from baseline in PASI versus placebo by Week 1. Significant improvement versus placebo was observed in all other efficacy measures by Week 8. Efficacy with deucravacitinib was maintained through Week 52. Conclusion: Deucravacitinib displayed efficacy as early as 1 week and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis. |
| format | Article |
| id | doaj-art-565ff6e9db3f40f3996833c3bba76026 |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-565ff6e9db3f40f3996833c3bba760262025-08-20T02:36:40ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2371045Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J. Korman0Richard B. Warren1Jerry Bagel2April W. Armstrong3Melinda Gooderham4Bruce Strober5Diamant Thaçi6Akimichi Morita7Shinichi Imafuku8Peter Foley9Howard Sofen10Min Zheng11Lauren Hippeli12Renata M. Kisa13Subhashis Banerjee14Andrew Blauvelt15Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USADermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UKPsoriasis Treatment Center of New Jersey, East Windsor, NJ, USAUniversity of California Los Angeles, Los Angeles, CA, USASKiN Centre for Dermatology, Peterborough, Queen’s University, Kingston, and Probity Medical Research, Waterloo, ON, CanadaYale University School of Medicine, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, USAInstitute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, GermanyGraduate School of Medical Sciences, Nagoya City University, Nagoya, JapanFaculty of Medicine, Fukuoka University Hospital, Fukuoka, JapanThe University of Melbourne, Parkville, St. Vincent’s Hospital Melbourne, Fitzroy, and Probity Medical Research and Skin Health Institute, Carlton, VIC, AustraliaUniversity of California Los Angeles, Los Angeles, CA, USAThe Second Affiliated Hospital and Zhejiang University School of Medicine, Hangzhou, ChinaBristol Myers Squibb, Princeton, NJ, USABristol Myers Squibb, Princeton, NJ, USABristol Myers Squibb, Princeton, NJ, USAOregon Medical Research Center, Portland, OR, USAAim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis evaluated onset of action and maintenance of response in patients randomized to deucravacitinib and placebo only. Methods: Adults with moderate to severe plaque psoriasis at baseline were randomized 1:2:1 to oral placebo, deucravacitinib, or apremilast. Onset of action was determined through changes from baseline in mean PASI, BSA, BSA × sPGA, and DLQI. Maintenance of response was assessed using PASI 75, PASI 90, PASI 100, sPGA 0/1, and sPGA 0 response rates through Week 52 in patients who were treated continuously with deucravacitinib, crossed over from placebo to deucravacitinib at Week 16, or received deucravacitinib and achieved PASI 75 by Week 24. Results: Deucravacitinib showed significantly higher increases in mean percent change from baseline in PASI versus placebo by Week 1. Significant improvement versus placebo was observed in all other efficacy measures by Week 8. Efficacy with deucravacitinib was maintained through Week 52. Conclusion: Deucravacitinib displayed efficacy as early as 1 week and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis.https://www.tandfonline.com/doi/10.1080/09546634.2024.2371045Clinical trialsdeucravacitinibmaintenance of responseonset of actionphase 3psoriasis |
| spellingShingle | Neil J. Korman Richard B. Warren Jerry Bagel April W. Armstrong Melinda Gooderham Bruce Strober Diamant Thaçi Akimichi Morita Shinichi Imafuku Peter Foley Howard Sofen Min Zheng Lauren Hippeli Renata M. Kisa Subhashis Banerjee Andrew Blauvelt Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials Journal of Dermatological Treatment Clinical trials deucravacitinib maintenance of response onset of action phase 3 psoriasis |
| title | Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials |
| title_full | Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials |
| title_fullStr | Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials |
| title_full_unstemmed | Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials |
| title_short | Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials |
| title_sort | deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials |
| topic | Clinical trials deucravacitinib maintenance of response onset of action phase 3 psoriasis |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2371045 |
| work_keys_str_mv | AT neiljkorman deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT richardbwarren deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT jerrybagel deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT aprilwarmstrong deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT melindagooderham deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT brucestrober deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT diamantthaci deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT akimichimorita deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT shinichiimafuku deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT peterfoley deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT howardsofen deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT minzheng deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT laurenhippeli deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT renatamkisa deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT subhashisbanerjee deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials AT andrewblauvelt deucravacitinibonsetofactionandmaintenanceofresponseinphase3plaquepsoriasistrials |